MYO · Myomo, Inc.

Myomo's first quarter 2026 results reflect continued progress in shifting toward recurring patient sources, which accounted for 49% of revenue, up from 25% a year ago. Revenue grew 3% year-over-year to $10.1 million, driven by a 9% increase in average selling price to approximately $58,800, partially offset by a 5% decline in units recognized (172 units). Gross margin expanded 100 basis points to 68.2%, benefiting from higher ASP and lower clinical costs. Operating expenses decreased 1% to $10.1 million, with lower R&D and G&A offsetting higher sales and marketing spend. The net loss narrowed to $3.0 million ($0.07 per share) from $3.5 million ($0.08 per share) in the prior year. Adjusted EBITDA improved 20% to $(2.3) million. Key operating metrics showed strength: pipeline adds of 723 patients (up 7% sequentially), orders received of 239 (up 12% year-over-year), and backlog of 226 patients (up 14% from year-end). Management highlighted the MyoConnect program's ramp-up, with 11% of pipeline adds and 16% of orders from direct billing referrals. The company guided Q2 2026 revenue in the range of $10.3 million to $10.8 million and reaffirmed full-year 2026 revenue guidance of $43 million to $46 million, with expectations of modestly higher operating expenses from increased advertising spend.